Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mds273
复制
发表时间：
2012-10-01
影响因子：
50.5
通讯作者：
Grp, E. S. M. O. Guidelines Working
中科院分区：
文献类型：
--
作者：
Tilly, H.;Vitolo, U.;Grp, E. S. M. O. Guidelines Working
弥漫性大b细胞淋巴瘤（DLBCL）占非霍奇金淋巴瘤系列的30%-58%。欧洲的原油发病率为3.8/10万/年。发病率随着年龄的增长而增加，在欧洲各地差异很大。淋巴瘤家族史、自身免疫性疾病、人类免疫缺陷病毒（HIV）感染、丙型肝炎病毒（HCV）血清阳性、年轻时高体重和一些职业暴露已被确定为DLBCL的危险因素。近年来，在所有欧洲地区，DLBCL的生存率都有了重要的改善。
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with age and varies considerably across Europe. A family history of lymphoma, autoimmune disease, human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) seropositivity, a high body mass as a young adult and some occupational exposures have been identified as risk factors of DLBCL [2]. In recent years, there have been important survival improvements for DLBCL in all European regions [3].